- On 30 October 2025, Novo Nordisk proposed to acquire Metsera, Inc.
- The revised offer on 6 November 2025 was 65.60 USD per share, valuing Metsera at 7.6 billion USD.
- Contingent value rights could add up to 20.65 USD per share based on milestones.
- Novo Nordisk will not increase its offer further.
Acquisition Proposal
On 30 October 2025, Novo Nordisk submitted an unsolicited proposal to acquire Metsera, Inc., which was deemed superior by Metsera's board of directors.
Revised Offers
On 4 November 2025, Novo Nordisk updated its offer to 62.20 USD per share, valuing Metsera at approximately 7.2 billion USD, with contingent value rights (CVRs) up to 24.00 USD per share based on certain milestones. On 6 November 2025, the offer was revised to 65.60 USD per share, increasing Metsera's valuation to 7.6 billion USD, with CVRs up to 20.65 USD per share.
Final Decision
Novo Nordisk decided not to increase its offer further, emphasizing its commitment to financial discipline and shareholder value.
Strategic Focus
Novo Nordisk continues to advance its pipeline for obesity treatments and invest in next-generation assets, while assessing business development opportunities that align with its strategic objectives.
